Relationship between hepatitis C virus infection and post transplantation diabetes mellitus: a meta-analysis

doi:10.3877/cma.j.issn.1674-3903.2020.02.014

Abstract

Abstract:

Objective

To use a meta-analysis system to evaluate whether hepatitis C virus (HCV) infection is a risk factor for post transplantation diabetes mellitus (PTDM) in kidney transplant recipients.

Methods

All the papers published up to December 2019 in Chinese journal full-text database, Chinese biomedical database, PubMed database, Embase database, Google scholar and Web of science database had been systematically searched. A meta-analysis was performed using a random effects model using Stata 15.1 software to calculate relative risk (RR).

Results

A total of 22 articles including 129 981 kidney transplant recipients were included. The results of meta-analysis showed that HCV infected recipients did have an relative risk of PTDM by about 2.5 times to non HCV infected recipients (RR=2.50, 95%CI: 1.95-3.20, P<0.001). Subgroup analysis based on race found that HCV infection was a significant risk factor for PTDM after kidney transplantation in Asian, Caucasian, and American races.

Conclusions

HCV infection is a risk factor that promotes PTDM in recipients after kidney transplantation. Infected recipients should be treated as soon as possible to elimate HCV.

Key words: Kidney transplantation, Post transplantation diabetes mellitus, Risk factor, Meta-analysis

Chao Li, Yanzhong Liu, Zhijia Liu, Hongwei Bai, Chen Yao, Xiaomei Xie, Gang Li, Fei Yu, Junjie Xie, Bingyi Shi. Relationship between hepatitis C virus infection and post transplantation diabetes mellitus: a meta-analysis[J]. Chinese Journal of Transplantation(Electronic Edition), 2020, 14(02): 118-123.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2020.02.014

https://zhyzzz.cma-cmc.com.cn/EN/Y2020/V14/I02/118

Figures/Tables 5

References 42

[1]	周代会，唐怡. 肾移植患者HCV感染的临床治疗研究进展[J]. 肝脏，2018, 23(8)：730-733.
[2]	Fabrizi F, Martin P, Dixit V, et al. Hepatitis C virus antibody and survival after renal transplantation: meta analysis of observational studies[J]. Am J Transplant, 2005, 5(6)：1452-1461.
[3]	Fernandes AR, Laranjinha IJ, Birne R, et al. HCV-infected renal transplant recipients：our experience before the availability of new antiviral drugs[J]. Int J Organ Transplant Med, 2017, 8(2)：104-109.
[4]	刘航，史屹，沈中阳. 肾移植术后新发糖尿病的危险因素及其对动脉僵硬度的影响[J]. 中华器官移植杂志，2009, 30(7)：415-418.
[5]	Khalili M, Lim WJ, Bass N, et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection[J]. Liver Transpl, 2004, 10(3): 349-355.
[6]	王红英. 关于丙肝病毒感染并发2型糖尿病的临床研究[J]. 心血管病防治知识(学术版), 2014, (2)：136-138.
[7]	Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology(MOOSE)group[J]. JAMA, 2000, 283(15)：2008-2012.
[8]	Panesar SS, Athanasiou T, Nair S, et al. Early outcomes in the elderly: a meta- analysis of 4921 patients undergoing coronary artery bypass grafting-comparison between off-pump and on-pump techniques[J]. Heart, 2006, 92(12)：1808-1816.
[9]	Athanasiou T, Al-Ruzzeh S, Kumar P, et al. Off-pump myocardial revascularization is associated with less incidence of stroke in elderly patients[J]. Ann Thorac Surg, 2004, 77(2)：745-753.
[10]	Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list[J]. Am J Transplant, 2005, 5(1): 139-144.
[11]	Yildiz A, Tutuncu Y, Yazici H, et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients[J]. Transplantation, 2002, 74(8)：1109-1113.
[12]	Gursoy M, Guvener N, Koksal R, et al. Impact of HCV infection on development of posttransplantation diabetes mellitus in renal allograft recipients[J]. Transplant Proc, 2000, 32(3): 561-562.
[13]	Gentil MA, Luna E, Rodriguez-Algarra G, et al. Incidence of diabetes mellitus requiring insulin treatment after renal transplantation in patients with hepatitis C[J]. Nephrol Dial Transplant, 2002, 17(5)：887-891.
[14]	Sens YAS, Silva VDST, Malafronte P, et al. Post-transplant diabetes mellitus in renal transplant patients with hepatitis C virus[J]. Transplant Proc, 2004, 36(4)：886-888.
[15]	Foo SM, Wong HS, Morad Z. Risk factors and incidence of posttransplant diabetes mellitus in renal transplant recipients[J]. Transplant Proc, 2004, 36(7)：2139-2140.
[16]	Gourishankar S, Jhangri GS, Tonelli M, et al. Development of diabetes mellitus following kidney transplantation: a Canadian experience[J]. Am J Transplant, 2004, 4(11)：1876-1882.
[17]	陈敏灵，张尧，于明香，等. 肾移植术后糖尿病的发病及其危险因素分析[J]. 中华内分泌代谢杂志，2013, 29(9)：750-755.
[18]	王英吉，狄文佳，孙勤，等. 肾移植术后糖尿病相关危险因素[J]. 肾脏病与透析肾移植杂志，2015, 24(1)：21-25.
[19]	Sezer S, Bilgic A, Uyar M, et al. Risk factors for development of posttransplant diabetes mellitus in renal transplant recipients[J]. Transplant Proc, 2006, 38(2)：529-532.
[20]	Schnitzler M, Kasiske BL, Snyder JJ, et al. Diabetes mellitus after kidney transplantation in the United States [1] (multiple letters)[J]. Am J Transplant, 2003, 3(10)：1318-1319.
[21]	Rodrigo E, De Cos MA, Fernández-Fresnedo G, et al. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus[J]. Transplant Proc, 2005, 37(9)：3819-3820.
[22]	Baid S, Tolkoff-Rubin N, Farrell ML, et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: Role of hepatitis C infection[J]. Transplant Proc, 2002, 34(5)：1771-1773.
[23]	Gentil MA, López M, González-Roncero F, et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: Influence of new immunosuppression protocols[J]. Transplant Proc, 2003, 35(5)：1748-1750.
[24]	Kamar N, Mariat C, Delahousse M, et al. Diabetes mellitus after kidney transplantation: A French multicentre observational study[J]. Nephrol Dial Transplant, 2007, 22(7)：1986-1993.
[25]	López Hidalgo R, Gentil MA, Acosta D, et al. Asociación entre diabetes mellitus y hepatitis C en trasplante renal[J]. Nefrologia, 2004, 24(6)：572-578.
[26]	Guleria S, Kamboj M, Chatterjee A, et al. Generic tacrolimus (Pan Graf) in renal transplantation: An experience of 155 recipients in India[J]. Transplant Proc, 2008, 40(7)：2237-2239.
[27]	Hirakauva EY, Ferraz MLG, Perez RM, et al. Prevalence of diabetes mellitus in renal transplant patients with hepatitis B or C virus infection[J]. Transplant Proc, 2002, 34(8)：3220-3222.
[28]	Liang J, Lv C, Chen M, et al. Effects of preoperative hepatitis B virus infection, hepatitis C virus infection, and coinfection on the development of new-onset diabetes after kidney transplantation[J]. J Diabetes, 2019, 11(5)：370-378.
[29]	Santos AH, Chen C, Casey MJ, et al. New-onset diabetes after kidney transplantation: Can the risk be modified by choosing immunosuppression regimen based on pretransplant viral serology？[J]. Nephrol Dial Transplant, 2018, 33(1)：177-184.
[30]	Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation[J]. Transplantation, 2006, 82(12)：1673-1676.
[31]	Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group[J]. Transplantation, 2000, 69(5)：875-880.
[32]	Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years[J]. Transplantation, 2001, 72(2): 245-250.
[33]	Margreiter A. A prospective, randomized multicentre study to compare the efficacy and safety of tacrolimus and cyclosporin microemulsion in renal transplantation[J]. Transplantation, 69(Suppl 8)：S112-S113.
[34]	Xie L, Tang W, Wang X, et al. Pretransplantation risk factors associated with new-onset diabetes after living-donor kidney transplantation[J]. Transplant Proc, 2016, 48(10)：3299-3302.
[35]	Gentil MA, Lopez M, Gonzalez-Roncero F, et al. Hepatitis C and the incidence of diabetes mellitus after renal transplant: influence of new immunosuppression protocols[J]. Transplant Proc, 2003, 35(5)：1748-1750.
[36]	杨进，方芳，杨富，等. 肾移植术后新发糖尿病：危险因素的回顾性分析[J]. 中国组织工程研究，2017, 21(20)：3275-3280.
[37]	Siraj ES, Abacan C, Chinnappa P, et al. Risk factors and outcomes associated with posttransplant diabetes mellitus in kidney transplant recipients[J]. Transplant Proc, 2010, 42(5)：1685-1689.
[38]	Hjelmesæth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance[J]. Nephrol Dial Transplantation, 2001, 16(4)：829-835.
[39]	Bergrem HA, Valderhaag TG, Hartmann A, et al. Glucose tolerance before and after renal transplantation[J]. Nephrol Dial Transplant, 2010, 25(3)：985-992.
[40]	Maldonado F, Tapia G, Ardiles L. Early hyperglycemia: a risk factor for posttransplant diabetes mellitus among renal transplant recipients[J]. Transplant Proc, 2009, 4l(6)：2664-2667.
[41]	Kaplan NM, Palmer BF, Mora PF. Post-transplantation diabetes mellitus[J]. Am J Med Sci, 2005, 329(2)：86-94.
[42]	Kurzawski M, Dziewanowski K, Droździk M. Analysis of type 2 diabetes mellitus genetic risk factors in relation to new onset diabetes after transplantation in renal transplant recipients medicated with tacrolimus[J]. Pharmacological Reports Pr, 2013, 65(1)：1-11.

纳入研究	发表年份(年)	国家	人种	肾移植受者例数(例)	HCV阳性[例(%)]	移植后糖尿病[例(%)]	随访时间(月)	文献质量评分(分)
Gursoy等^[12]	2000	土耳其	高加索	247	40(16)	40(16)	39	8
Hirakauva等^[27]	2002	巴西	美洲	227	227(77)	33(15)	72	7
Baid等^[22]	2002	美国	美洲	114	18(16)	7(39)	12	6
Yildiz等^[11]	2002	土耳其	高加索	86	47(55)	43(50)	24	6
Gentil等^[13]	2002	西班牙	高加索	354	177(50)	28( 8)	44	7
Kasiske等^[20]	2003	美国	美洲	11 659	658( 6)	2 798(24)	48	8
Gentil等^[23]	2003	西班牙	高加索	570	123(23)	55(10)	95.6	7
López Hidalgo等^[25]	2004	塞维利亚	高加索	325	94(29)	72(22)	18	6
Sens等^[14]	2004	巴西	美洲	50	25(50)	9(18)	29	8
Foo等^[15]	2004	马来西亚	亚洲	316	89(28)	42(13)	125	6
Gourishankar等^[16]	2004	加拿大	高加索	386	11( 3)	35(10)	44	6
Bloom等^[10]	2005	美国	美洲	427	71(17)	63(15)	41	6
Rodrigo等^[21]	2005	西班牙	高加索	73	5( 7)	20(27)	108	6
Sezer等^[19]	2006	土耳其	高加索	204	24(12)	26(13)	21.6	6
Shah等^[30]	2006	美国	美洲	15 309	646( 4)	1 531(10)	10	8
Kamar等^[24]	2007	法国	高加索	527	19( 4)	37( 7)	24	6
Guleria等^[26]	2008	印度	亚洲	155	9( 6)	26(18)	16	6
Liu等^[4]	2009	中国	亚洲	195	16( 8)	29(15)	12	6
Chen等^[17]	2013	中国	亚洲	428	45(11)	87(20)	67	5
Wang等^[18]	2015	中国	亚洲	128	13(10)	51(40)	12	5
Santos等^[29]	2018	美国	美洲	97 644	3 850( 4)	无数据	60	8
Liang等^[28]	2019	中国	亚洲	557	41( 7)	120(22)	96	7

纳入研究	发表年份(年)	国家	人种	肾移植受者例数(例)	HCV阳性[例(%)]	移植后糖尿病[例(%)]	随访时间(月)	文献质量评分(分)
Gursoy等^[12]	2000	土耳其	高加索	247	40(16)	40(16)	39	8
Hirakauva等^[27]	2002	巴西	美洲	227	227(77)	33(15)	72	7
Baid等^[22]	2002	美国	美洲	114	18(16)	7(39)	12	6
Yildiz等^[11]	2002	土耳其	高加索	86	47(55)	43(50)	24	6
Gentil等^[13]	2002	西班牙	高加索	354	177(50)	28( 8)	44	7
Kasiske等^[20]	2003	美国	美洲	11 659	658( 6)	2 798(24)	48	8
Gentil等^[23]	2003	西班牙	高加索	570	123(23)	55(10)	95.6	7
López Hidalgo等^[25]	2004	塞维利亚	高加索	325	94(29)	72(22)	18	6
Sens等^[14]	2004	巴西	美洲	50	25(50)	9(18)	29	8
Foo等^[15]	2004	马来西亚	亚洲	316	89(28)	42(13)	125	6
Gourishankar等^[16]	2004	加拿大	高加索	386	11( 3)	35(10)	44	6
Bloom等^[10]	2005	美国	美洲	427	71(17)	63(15)	41	6
Rodrigo等^[21]	2005	西班牙	高加索	73	5( 7)	20(27)	108	6
Sezer等^[19]	2006	土耳其	高加索	204	24(12)	26(13)	21.6	6
Shah等^[30]	2006	美国	美洲	15 309	646( 4)	1 531(10)	10	8
Kamar等^[24]	2007	法国	高加索	527	19( 4)	37( 7)	24	6
Guleria等^[26]	2008	印度	亚洲	155	9( 6)	26(18)	16	6
Liu等^[4]	2009	中国	亚洲	195	16( 8)	29(15)	12	6
Chen等^[17]	2013	中国	亚洲	428	45(11)	87(20)	67	5
Wang等^[18]	2015	中国	亚洲	128	13(10)	51(40)	12	5
Santos等^[29]	2018	美国	美洲	97 644	3 850( 4)	无数据	60	8
Liang等^[28]	2019	中国	亚洲	557	41( 7)	120(22)	96	7

Please choose a citation manager

Content to export